Lakhtakia R, Nema S K
Senior Advisor (Pathology), CH (CC) Lucknow.
DDMS, HQ 10 Corps, C/o 56 APO.
Med J Armed Forces India. 2008 Jan;64(1):16-20. doi: 10.1016/S0377-1237(08)80138-4. Epub 2011 Jul 21.
Immunophenotyping has added a new dimension to improve the diagnostic accuracy of malignant diseases. The emphasis is on its usefulness in planning and institution of specific therapy besides helping in prognostication.
The study included 83/1385 biopsies of cancer patients over an 18 month period on which immunohistochemical staining (IHC) with monoclonal antibodies were performed. The technique was used to establish the histogenetic origins/expression of the tumours. The study excluded haematolymphoid malignancies.
Eighty three cases on whom IHC was performed included poorly differentiated tumours (15), metastatic tumours (16), soft tissue tumours (35), central nervous system tumours (9) and miscellaneous (6). Two cases could not be typed. The clinicopathological correlation in terms of the management and the problems related to its misinterpretation are discussed.
Immunophenotyping of tumours in an oncology set up is significant in the 'Final Diagnosis'.
免疫表型分析为提高恶性疾病的诊断准确性增添了新的维度。除了有助于预后判断外,其重点在于在规划和实施特定治疗方面的实用性。
该研究纳入了18个月期间83例/1385例癌症患者的活检样本,对其进行了单克隆抗体免疫组织化学染色(IHC)。该技术用于确定肿瘤的组织发生起源/表达情况。该研究排除了血液淋巴系统恶性肿瘤。
接受IHC检测的83例病例包括低分化肿瘤(15例)、转移性肿瘤(16例)、软组织肿瘤(35例)、中枢神经系统肿瘤(9例)和其他(6例)。2例无法分型。讨论了在管理方面的临床病理相关性以及与其错误解读相关的问题。
肿瘤学环境中肿瘤的免疫表型分析在“最终诊断”中具有重要意义。